KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Q3 2025 value amounting to $649000.0.

  • Biomarin Pharmaceutical's Amortization of Deferred Charges fell 961.0% to $649000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 2873.41%. This contributed to the annual value of $3.4 million for FY2024, which is 1979.47% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Amortization of Deferred Charges of $649000.0 as of Q3 2025, which was down 961.0% from $660000.0 recorded in Q2 2025.
  • Biomarin Pharmaceutical's Amortization of Deferred Charges' 5-year high stood at $1.1 million during Q3 2023, with a 5-year trough of $649000.0 in Q3 2025.
  • For the 5-year period, Biomarin Pharmaceutical's Amortization of Deferred Charges averaged around $935736.8, with its median value being $1.0 million (2022).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Amortization of Deferred Charges tumbled by 8027.52% in 2021 and then skyrocketed by 1100.29% in 2023.
  • Biomarin Pharmaceutical's Amortization of Deferred Charges (Quarter) stood at $1.0 million in 2021, then dropped by 0.39% to $1.0 million in 2022, then fell by 3.7% to $990000.0 in 2023, then crashed by 33.33% to $660000.0 in 2024, then dropped by 1.67% to $649000.0 in 2025.
  • Its last three reported values are $649000.0 in Q3 2025, $660000.0 for Q2 2025, and $660000.0 during Q1 2025.